CD8A and breast neoplasm: In addition, a recombinant TWIST1 protein has been used as a vaccine to induce both CD8+ and CD4+ TWIST1-specific T-cell responses in vivo to attack TWIST1-expressing breast tumor cells with certain efficacy [71].